Clinical Guidelines
AAO Recap: 3.5-Year Observations from the GATHER2 Open-Label Extension (OLE) Trial
-
By
-
February 26, 2026
-
2 min
-
1
Dr. Arshad Khanani presented GATHER2 trial results at AAO.
-
2
The trial studied Avacincaptad Pegol for geographic atrophy treatment.
-
3
Monitoring for neovascular AMD is essential.
-
4
Key adverse reactions included conjunctival hemorrhage and blurred vision.
-
5
Intravitreal injections carry risks, including endophthalmitis.
-
6
IOP may increase temporarily post-injection.
-
7
Safety protocols are crucial in administration.
